Efficacy and Tolerability of a Hepatoprotective Nutraceutical Formulation in Dogs with Iatrogenic Hepatocellular Injury: A Retrospective Observational Study

Authors

  • Bruna de Felice Department of Environmental , Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, Italy
  • Gianluca Barbato Barbato Clinic Pathology and Clinic for Companion Animals, Via Milano snc, Pachino (SR), Italy
  • Elisa De Paoli Self-employed Veterinarian, Italy
  • Barbara D'Orta Self-employed Veterinarian, Italy
  • Youssef Khalidy Self-employed Veterinarian, Italy
  • Francesco Pascali Self-employed Veterinarian, Italy
  • Barbara Pantalone Self-employed Veterinarian, Italy
  • Paolo Rosi Self-employed Veterinarian, Italy
  • Greta Trussardi Self-employed Veterinarian, Italy
  • Alessandra Zucca Self-employed Veterinarian, Italy
  • Andrea Del Buono DDClinic EPS Research, Caserta, Italy

DOI:

https://doi.org/10.14738/bjhr.1304.11954

Abstract

Objective: To evaluate longitudinal changes in hepatocellular enzyme activity in dogs nutritionally supplemented with a complementary feed 1 based on carrot ( Daucus carota L. ) extract rich in superoxide dismutase (SOD) from phytocomplexes, to modulate hypertransaminasemia induced by therapies for canine leishmaniasis. Methods: Retrospective observational study of 30 client-owned dogs with alanine aminotransferase (ALT) and aspartate transaminase (AST) activity 4 times the reference limit at T0 and reevaluated every month. The endpoints: ALT, AST were assessed at T0, T3, T6, and T12 months. Statistical analysis: ANOVA for repeated measures with Bonferroni correction and Effect Size ( Cohen's D ). Results: ALT activity decreased significantly at T12 - P < .001 . Ninety percent of dogs achieved biochemical normalization within 12 months. Tolerability was 96%. Conclusions: Supplementation showed a clinically relevant reduction in cytolysis markers . The robustness of the effect ( Cohen's d = 2.8 ) supports the efficacy of the formulation in the support of iatrogenic liver injury. Observation and Limitations: Retrospective design • No untreated control group • Limited biomarker panel • No histopathological confirmation • Moderate sample size. Retrospective analysis of medical records; no experimental interventions were performed.

References

Cortese L, Pelagalli A, Piantedosi D, Mastellone V, Manna L, d'Angelo D, et al. Safety and effectiveness of a nutritional supplement in dogs with oxidative stress and hepatocellular injury. J Vet Intern Med. 2020;34(4):1452-1461.

Roura X, Arena J, Baseccia A, et al. Iatrogenic liver injury associated with leishmaniasis drug protocols in dogs: a retrospective assessment. Vet Parasitol. 2019;268:45-52.

Skoritzinsky M, Ribeiro M, Santos I. Evaluation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities during canine leishmaniasis treatment. Parasites & Vectors. 2021;14(1):112.

Trapp SM, Iacono FH, Takahira RK. Hepatoprotective effects of Silybum marianum (Milk Thistle) on drug-induced liver injury in canine models. Vet Clin Pathol. 2018;47(2):233-241.

European Food Safety Authority (EFSA). Scientific Opinion on the safety and efficacy of carrot extract (Daucus carota L.) rich in superoxide dismutase as a feed additive for dogs and cats. EFSA Journal. 2022;20(3):7150.

Vandeweerd JM, Cambier C, Gustin P. Total antioxidant capacity and superoxide dismutase activity in dogs undergoing leishmanicidal therapy: modulation by phytocomplexes. BMC Vet Res. 2021;17(1):89.

Webster CRL, Center SA, Cullen JM, et al. ACVIM consensus statement on the diagnosis and management of acute kidney injury and hepatotoxicity in dogs and cats. J Vet Intern Med. 2019;33(3):1173-1200.

Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.

Downloads

Published

2026-07-05

How to Cite

Felice, B., Barbato, G., Paoli, E., D’Orta, B., Khalidy, Y., Pascali, F., … Buono, A. D. (2026). Efficacy and Tolerability of a Hepatoprotective Nutraceutical Formulation in Dogs with Iatrogenic Hepatocellular Injury: A Retrospective Observational Study. British Journal of Healthcare and Medical Research, 13(04), 17–20. https://doi.org/10.14738/bjhr.1304.11954